Crossmark

Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection

Crossref DOI link: https://doi.org/10.1007/s11596-021-2363-9

Published Online: 2021-05-28

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahmed, Manar

Mansey, Azza E.

Wahsh, Engy A.

Gomaa, Ahmed A.

Rabea, Hoda M.
License Information

Text and Data Mining valid from 2021-05-28

Version of Record valid from 2021-05-28
More Information

Article History

Received: 31 December 2019

Accepted: 11 December 2020

First Online: 28 May 2021

Conflict of Interest Statement

: The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below